According to Globus Medical's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 35.652. At the end of 2022 the company had a P/E ratio of 39.3.
Year | P/E ratio | Change |
---|---|---|
2022 | 39.3 | -19.45% |
2021 | 48.8 | -22.21% |
2020 | 62.7 | 68.28% |
2019 | 37.3 | 37.77% |
2018 | 27.0 | -26.29% |
2017 | 36.7 | 59.74% |
2016 | 23.0 | -2.56% |
2015 | 23.6 | -2.8% |
2014 | 24.3 | -11.06% |
2013 | 27.3 | 124.03% |
2012 | 12.2 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
![]() | 73.6 | 106.47% | ๐บ๐ธ USA |
![]() | 54.2 | 51.99% | ๐บ๐ธ USA |
![]() | -4.43 | -112.43% | ๐บ๐ธ USA |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.